Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosisPietro Lampertico, M. Colombo, María Rízzí et al.|Digestive and Liver Disease|2014Cited by 23
Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohortAlessandro Soria, G. Aimo, Marco Fava et al.|Liver International|2020Cited by 19
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life studyRoberta D’Ambrosio, S. Fagiuoli, L. Pasulo et al.|Digestive and Liver Disease|2019Cited by 17
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II studyRoberta D’Ambrosio, S. Fagiuoli, L. Pasulo et al.|Journal of Hepatology|2018Cited by 12
OC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICEPietro Lampertico, M. Colombo, R. Soffredini et al.|Digestive and Liver Disease|2012Cited by 11